
    
      This is a compassionate use open label program in patients hospitalized with pulmonary
      complications of SARS-CoV-2 infection who will receive IC14 at a dosage of 4 mg/kg on Day 1,
      then 2 mg/kg once daily on Days 2-4. Patient monitoring will be for a total of up to 28 days
      if the patient is still hospitalized.

      Screening/baseline assessments and initiation of the first IC14 administration will occur
      within 48 hours after meeting inclusion criteria. IC14 should be administered at
      approximately 24-hr intervals beginning from the start time of the first IC14 administration
      (Day 1).
    
  